Lucia Nogová

Evaluation of BGJ398, a Fibroblast Growth Factor Receptor 1-3 Kinase Inhibitor, in Patients With Advanced Solid Tumors Harboring Genetic Alterations in Fibroblast Growth Factor Receptors: Results of a Global Phase I, Dose-Escalation and Dose-Expansion Study

Lucia Nogová, Lecia V. Sequist, José Manuel Pérez García et al. · Journal of Clinical Oncology · 2017 · 419 citations

Antitumor Activity, Pathology, Global Phase +17

K-ras Mutation Subtypes in NSCLC and Associated Co-occuring Mutations in Other Oncogenic Pathways

Matthias Scheffler, Michaela A. Ihle, Rebecca Hein et al. · Journal of Thoracic Oncology · 2018 · 247 citations · Full text

Impact of TP53 mutation status on systemic treatment outcome in ALK-rearranged non-small-cell lung cancer

Anna Kron, Christina Alidousty, Matthias Scheffler et al. · Annals of Oncology · 2018 · 207 citations · Full text

Early Prediction of Nonprogression in Advanced Non–Small-Cell Lung Cancer Treated With Erlotinib By Using [¹⁸F]Fluorodeoxyglucose and [¹⁸F]Fluorothymidine Positron Emission Tomography

Thomas Zander, Matthias Scheffler, Lucia Nogová et al. · Journal of Clinical Oncology · 2011 · 171 citations · Full text

Efficacy of everolimus (RAD001) in patients with advanced NSCLC previously treated with chemotherapy alone or with chemotherapy and EGFR inhibitors

Jean‐Charles Soria, Frances A. Shepherd, Jean‐Yves Douillard et al. · Annals of Oncology · 2009 · 164 citations

Advanced Nsclc, Oncology, Pharmacology +6